Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Travere Therapeutics Inc's Business Segments
Travere Therapeutics Inc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of Q2 FY2026
Reportable Segments
1
Largest Segment
Reportable
Total Revenue
$ 170
Regions Reported
-
Revenue Share by Reportable Segment - Q2 FY2026
- Reportable100%
Revenue by Reportable Segment - Q2 FY2026
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Reportable | $ 170 | 100% |
Revenue by Product & Service Category - Q2 FY2026
- Product95.1%
- FILSPARI83.2%
- Tiopronin products12%
- License4.9%
Revenue by Product & Service Category - Q2 FY2026
| Category | Revenue (Millions) | % of Total |
|---|---|---|
| Product | $ 161 | 95.1% |
| FILSPARI | $ 141 | 83.2% |
| Tiopronin products | $ 20 | 12% |
Product and service categories are a supplemental disclosure and are not required to sum to consolidated revenue or to the reportable segments above.
1 more categories available
Sign in to unlock the full Travere Therapeutics Inc dataset.
Description of Travere Therapeutics Inc
Travere Therapeutics Inc. is a pharmaceutical company that specializes in developing and commercializing treatments for rare and complex diseases. The company was founded in 1988 as Raptor Pharmaceuticals Corp. and was later renamed TRC Capital Corporation in 2018 before changing to its current name in 2019.
Travere Therapeutics focuses on developing treatments for chronic kidney disease, a group of complex and progressive conditions that damage the kidneys over time, leading to a range of health problems. The company has several drugs in its pipeline aimed at treating various forms of chronic kidney disease and other rare disorders.
One of the company's key products is called JYNARQUE® (tolvaptan), a treatment for adult patients with autosomal dominant polycystic kidney disease (ADPKD). ADPKD is a genetic disorder that causes cysts to develop and enlarge in the kidneys, resulting in a range of complications including kidney failure, high blood pressure, and liver cysts. JYNARQUE® is the first FDA-approved treatment for ADPKD and works by decreasing the rate of kidney enlargement and disease progression.
Another product in Travere Therapeutics' pipeline is sparsentan, an investigational drug currently in Phase 3 clinical trials for the treatment of focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN). FSGS and IgAN are two other types of chronic kidney disease that can lead to kidney failure if left untreated.
Travere Therapeutics also has a robust research and development program focused on the development of treatments for other rare and complex diseases. They have partnerships with other pharmaceutical companies and academic institutions to develop new therapies and bring them to market.
In addition to its drug development efforts, Travere Therapeutics is committed to working with patient advocacy groups to raise awareness about rare diseases and improve patient outcomes. The company also has a patient support program that provides assistance to patients who are prescribed its drugs, including financial assistance and access to educational resources.
Overall, Travere Therapeutics is a leading pharmaceutical company specializing in the development of treatments for rare and complex diseases, particularly chronic kidney disease. With an active pipeline of drug candidates and a commitment to patient advocacy, Travere Therapeutics is poised to make a significant impact on the healthcare industry.
Travere Therapeutics focuses on developing treatments for chronic kidney disease, a group of complex and progressive conditions that damage the kidneys over time, leading to a range of health problems. The company has several drugs in its pipeline aimed at treating various forms of chronic kidney disease and other rare disorders.
One of the company's key products is called JYNARQUE® (tolvaptan), a treatment for adult patients with autosomal dominant polycystic kidney disease (ADPKD). ADPKD is a genetic disorder that causes cysts to develop and enlarge in the kidneys, resulting in a range of complications including kidney failure, high blood pressure, and liver cysts. JYNARQUE® is the first FDA-approved treatment for ADPKD and works by decreasing the rate of kidney enlargement and disease progression.
Another product in Travere Therapeutics' pipeline is sparsentan, an investigational drug currently in Phase 3 clinical trials for the treatment of focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN). FSGS and IgAN are two other types of chronic kidney disease that can lead to kidney failure if left untreated.
Travere Therapeutics also has a robust research and development program focused on the development of treatments for other rare and complex diseases. They have partnerships with other pharmaceutical companies and academic institutions to develop new therapies and bring them to market.
In addition to its drug development efforts, Travere Therapeutics is committed to working with patient advocacy groups to raise awareness about rare diseases and improve patient outcomes. The company also has a patient support program that provides assistance to patients who are prescribed its drugs, including financial assistance and access to educational resources.
Overall, Travere Therapeutics is a leading pharmaceutical company specializing in the development of treatments for rare and complex diseases, particularly chronic kidney disease. With an active pipeline of drug candidates and a commitment to patient advocacy, Travere Therapeutics is poised to make a significant impact on the healthcare industry.
Travere Therapeutics Inc. Overview
Travere Therapeutics Inc. is a biopharmaceutical company committed to creating transformative medicines aimed at meeting the needs of patients afflicted with rare and complex diseases. The company is recognized for its deep knowledge of the mechanisms underlying these conditions and the innovative approaches it takes to develop therapies that promote better health outcomes.
Business Segments
Travere Therapeutics has structured its operations into two primary segments:
1. Rare Disease Segment
The Rare Disease Segment emphasizes innovative therapeutic solutions for rare genetic disorders. The company employs a scientific approach that underlines its commitment to understanding the biology of the specific conditions it targets. In this segment, Travere focuses on three primary platforms:
- Rett Syndrome: The company is actively developing TRV-880, a novel therapeutic candidate tailored specifically for treating Rett Syndrome, a progressive neurological disorder that predominantly affects females. This drug aims to address the underlying mechanisms of the disease in order to offer significant relief from the debilitating symptoms.
- Neurogenic Orthostatic Hypotension (nOH): This debilitating condition arises from the malfunctioning of the autonomic nervous system, resulting in a severe drop in blood pressure upon standing. Travere has initiated a pipeline of therapies aimed at managing the symptoms and improving the quality of life for those affected.
- Autosomal Dominant Polycystic Kidney Disease (ADPKD): This inherited disorder is characterized by the proliferation of cysts in the kidneys. The company is exploring various treatment modalities to slow disease progression and improve kidney function in affected patients.
Nephrology Segment
In addition to rare diseases, Travere Therapeutics possesses a dedicated Nephrology Segment that focuses on kidney diseases and conditions. This segment enhances patient care by developing products and solutions geared toward improving renal health and patient outcomes:
- Hyperoxaluria: This condition results in excessive oxalate in the urine, leading to kidney stones and potential renal failure. Traveres flagship product, Thiola EC, plays a crucial role in managing cystinuria—a type of hyperoxaluria by minimizing cystine excretion, thus helping to prevent stone formation.
Products
The product portfolio of Travere Therapeutics comprises a blend of approved commercial products and investigational therapies:
1. Thiola EC:
- This is Travere’s inaugural commercial product, primarily indicated for cystinuria, a rare genetic disorder that leads to the formation of cystine stones in the urinary tract. It provides a biochemically integrated approach by reducing cystine levels in the urine, helping to thwart the emergence of new kidney stones.
2. TRV-801:
- Targeting Pompe disease—a severe genetic condition that impairs muscle and respiratory function—TRV-801 is in development as a long-acting enzyme replacement therapy (ERT). Its design aims to provide consistent therapeutic levels of the enzyme, potentially improving patient compliance and overall treatment efficacy.
3. TRV-738:
- This investigational drug is being developed for Alport syndrome, a rare and progressive kidney disease. TRV-738 operates on a molecular mechanism that reduces the expression of proteins implicated in the disease’s progression, potentially altering its natural course.
Services
To complement its product offerings, Travere Therapeutics provides a suite of services designed to enhance patient experience and treatment adherence:
1. Patient Support Programs:
- These programs are tailored to deliver personalized assistance to individuals utilizing Travere’s products. All-encompassing, the services include education about the disease and treatment management, as well as financial assistance options to navigate the costs associated with therapy. This holistic approach ensures that patients receive comprehensive support throughout their treatment journey.
2. Clinical Trials:
- The company is deeply invested in clinical research, conducting trials to evaluate the safety and effectiveness of new therapeutic candidates. These trials are critical for gathering robust data necessary for regulatory approvals and ensuring that novel treatments meet the required standards before reaching the market.
Summary
In summary, Travere Therapeutics Inc. stands at the forefront of biopharmaceutical innovation, focusing on rare and complex genetic diseases with a commitment to comprehensive patient care. The company’s strategic segmentation allows for targeted research and development efforts, with products like Thiola EC, TRV-801, and TRV-738 addressing significant medical needs. Additionally, their patient support programs and clinical trial initiatives exemplify a holistic approach to healthcare, ensuring that patients not only receive cutting-edge therapies but also the necessary support to manage their conditions effectively.
Travere Therapeutics Inc. is a biopharmaceutical company committed to creating transformative medicines aimed at meeting the needs of patients afflicted with rare and complex diseases. The company is recognized for its deep knowledge of the mechanisms underlying these conditions and the innovative approaches it takes to develop therapies that promote better health outcomes.
Business Segments
Travere Therapeutics has structured its operations into two primary segments:
1. Rare Disease Segment
The Rare Disease Segment emphasizes innovative therapeutic solutions for rare genetic disorders. The company employs a scientific approach that underlines its commitment to understanding the biology of the specific conditions it targets. In this segment, Travere focuses on three primary platforms:
- Rett Syndrome: The company is actively developing TRV-880, a novel therapeutic candidate tailored specifically for treating Rett Syndrome, a progressive neurological disorder that predominantly affects females. This drug aims to address the underlying mechanisms of the disease in order to offer significant relief from the debilitating symptoms.
- Neurogenic Orthostatic Hypotension (nOH): This debilitating condition arises from the malfunctioning of the autonomic nervous system, resulting in a severe drop in blood pressure upon standing. Travere has initiated a pipeline of therapies aimed at managing the symptoms and improving the quality of life for those affected.
- Autosomal Dominant Polycystic Kidney Disease (ADPKD): This inherited disorder is characterized by the proliferation of cysts in the kidneys. The company is exploring various treatment modalities to slow disease progression and improve kidney function in affected patients.
Nephrology Segment
In addition to rare diseases, Travere Therapeutics possesses a dedicated Nephrology Segment that focuses on kidney diseases and conditions. This segment enhances patient care by developing products and solutions geared toward improving renal health and patient outcomes:
- Hyperoxaluria: This condition results in excessive oxalate in the urine, leading to kidney stones and potential renal failure. Traveres flagship product, Thiola EC, plays a crucial role in managing cystinuria—a type of hyperoxaluria by minimizing cystine excretion, thus helping to prevent stone formation.
Products
The product portfolio of Travere Therapeutics comprises a blend of approved commercial products and investigational therapies:
1. Thiola EC:
- This is Travere’s inaugural commercial product, primarily indicated for cystinuria, a rare genetic disorder that leads to the formation of cystine stones in the urinary tract. It provides a biochemically integrated approach by reducing cystine levels in the urine, helping to thwart the emergence of new kidney stones.
2. TRV-801:
- Targeting Pompe disease—a severe genetic condition that impairs muscle and respiratory function—TRV-801 is in development as a long-acting enzyme replacement therapy (ERT). Its design aims to provide consistent therapeutic levels of the enzyme, potentially improving patient compliance and overall treatment efficacy.
3. TRV-738:
- This investigational drug is being developed for Alport syndrome, a rare and progressive kidney disease. TRV-738 operates on a molecular mechanism that reduces the expression of proteins implicated in the disease’s progression, potentially altering its natural course.
Services
To complement its product offerings, Travere Therapeutics provides a suite of services designed to enhance patient experience and treatment adherence:
1. Patient Support Programs:
- These programs are tailored to deliver personalized assistance to individuals utilizing Travere’s products. All-encompassing, the services include education about the disease and treatment management, as well as financial assistance options to navigate the costs associated with therapy. This holistic approach ensures that patients receive comprehensive support throughout their treatment journey.
2. Clinical Trials:
- The company is deeply invested in clinical research, conducting trials to evaluate the safety and effectiveness of new therapeutic candidates. These trials are critical for gathering robust data necessary for regulatory approvals and ensuring that novel treatments meet the required standards before reaching the market.
Summary
In summary, Travere Therapeutics Inc. stands at the forefront of biopharmaceutical innovation, focusing on rare and complex genetic diseases with a commitment to comprehensive patient care. The company’s strategic segmentation allows for targeted research and development efforts, with products like Thiola EC, TRV-801, and TRV-738 addressing significant medical needs. Additionally, their patient support programs and clinical trial initiatives exemplify a holistic approach to healthcare, ensuring that patients not only receive cutting-edge therapies but also the necessary support to manage their conditions effectively.